Size and Treatment Outcomes of HR+, HER2- Early Breast Cancer Population With High Risk of Recurrence: A Real-World Cohort Study With Danish Breast Cancer Cooperative Group Registry Data
# Background While the prognosis is generally good for hormone receptor–positive (HR+), human epidermal growth factor–negative (HER2–) early breast cancer (EBC) patients, up to 30% of patients with high-risk clinical and/or pathologic features experience recurrence. # Objectives This retrospective...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Columbia Data Analytics, LLC
2025-06-01
|
| coleção: | Journal of Health Economics and Outcomes Research |
| Acesso em linha: | https://doi.org/10.36469/001c.137277 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|